secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-08-14T20:00:21+00:00
Accession:  0001193125-26-352126
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma Q2 net loss $153M, revenue $7.9M, $50M PIPE
---------------------------------------------------------

- Q2 revenue $7.9M vs $3.0M YoY; net loss $153.1M vs $8.5M, driven by one-time charges.
- R&D expenses $49.0M incl. $20M cash to Ascendant and $20M warrant fair value; G&A $46.6M incl. $23M integration and $19.7M stock comp.
- Cash $17.4M at June 30; completed $50M private placement after quarter-end.
- Submitted IND to FDA for CUE-221 in food allergy; Phase 2 data in chronic spontaneous urticaria expected by end of Q3 2026.
- Appointed Dr. Dominic Borie as CMO/Head of R&D and James M. Ahlers as CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/0001193125-26-352126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-352126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer